UK life science competitiveness indicators 2022: measuring what matters most? The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July Share X UK life science competitiveness indicators 2022: measuring what matters most? https://pharmaphorum.com/market-access-2/uk-life-science-competitiveness-indicators-2022-measuring-what-matters-most/
Why reshoring drug production means embracing continuous manufacturing Recent history should have the pharmaceutical industry questioning some of its fundamental assumptions. The COVID-19 pandemic led to Share X Why reshoring drug production means embracing continuous manufacturing https://pharmaphorum.com/market-access-2/why-reshoring-drug-production-means-embracing-continuous-manufacturing/
Philips on designing innovation and cultivating partnerships – part two This article follows part one of our two-part series, where we discussed how Philips designs innovation and digital Share X Philips on designing innovation and cultivating partnerships – part two https://pharmaphorum.com/market-access-2/philips-on-designing-innovation-and-cultivating-partnerships-part-two/
Global comparator data signal “alarm bells” for UK Government, says APBI Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Despite the UK’s Share X Global comparator data signal “alarm bells” for UK Government, says APBI https://pharmaphorum.com/market-access-2/global-comparator-data-signal-alarm-bells-for-uk-government-says-apbi/
Philips on designing innovation and cultivating partnerships – part one Sachin Grover, lead of solutions vertical at Philips India, tells me about the company’s innovations during India’s COVID Share X Philips on designing innovation and cultivating partnerships – part one https://pharmaphorum.com/market-access-2/philips-on-designing-innovation-and-cultivating-partnerships-part-one/
The new European Unitary Patent system – What you need to know The proposed European unitary patent and unified patent court represents one of the largest changes to the European Share X The new European Unitary Patent system – What you need to know https://pharmaphorum.com/market-access-2/the-new-european-unitary-patent-system-what-you-need-to-know/
As FDA inspections return, upholding compliance and maintaining GMP readiness is more crucial than ever The pharmaceutical industry has long been highly regulated to help ensure quality and safety across all aspects of Share X As FDA inspections return, upholding compliance and maintaining GMP readiness is more crucial than ever https://pharmaphorum.com/market-access-2/fda-inspections-return-maintaining-gmp-readiness-is-more-crucial-than-ever/
The big squeeze? With NHS England highlighting savings of £1.2 billion on medicines in three years coming from both deals on Share X The big squeeze? https://pharmaphorum.com/market-access-2/the-big-squeeze/
Are timely access and robust safety mutually exclusive? The FDA approves new cancer treatments in half the time of the EMA – but does faster mean Share X Are timely access and robust safety mutually exclusive? https://pharmaphorum.com/market-access-2/are-timely-access-and-robust-safety-mutually-exclusive/
